As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology. Matinas’ lead LNC-based therapy is ...

Matinas BioPharma Holdings ... which was generated from research collaborations with BioNTech and Genentech. Total cost and expenses for the first six months of 2024 were $11.7 million, compared ...

Earnings call: Matinas BioPharma outlines progress on MAT2203 and LNC platform ...

Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical ... which was generated from research collaborations with BioNTech (NASDAQ:BNTX) and Genentech. Total cost and expenses for ...